Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M302Revenue $M5.2Net Margin (%)-708.4Altman Z-Score-1.6
Enterprise Value $M311EPS $-0.6Operating Margin %-976.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-991.5Higher ROA y-yY
Price/Book12.510-y EBITDA Growth Rate %32.7Quick Ratio3.4Cash flow > EarningsY
Price/Sales47.75-y EBITDA Growth Rate %45.2Current Ratio3.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-59.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-173.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M83.3ROIC % (ttm)-872.7Gross Margin Increase y-yN

Gurus Latest Trades with BTX

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Russell Angus C.Director 2014-12-12Sell0$0 view
Cartt Stephen LaHueDirector 2014-11-04Sell0$0 view
FARRELL STEPHEN CDirector 2014-10-08Buy32,050$3.1216.35 view
SCHLACHET DAVIDDirector 2014-10-08Buy32,050$3.1216.35 view
Peabody RobertSr. VP, COO, and CFO 2014-07-22Sell100,000$2.6536.98 view
WEST MICHAEL DCEO 2014-07-22Sell270,000$2.6536.98 view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-07-22Buy370,000$2.6536.98 view
TEW WILLIAM P PHDChief Commercial Officer 2014-06-17Sell30,000$3.0718.24 view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-06-16Buy1,000,000$2.545.2 view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-05-16Buy300,000$2.4548.16 view

Quarterly/Annual Reports about BTX:

News about BTX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
William Annett Named Chief Executive Officer of OncoCyte Corporation Jun 16 2015
William Annett Named Chief Executive Officer of OncoCyte Corporation Jun 16 2015
BioTime to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
BioTime to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of... May 19 2015
OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of... May 19 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure May 19 2015
BIOTIME INC Financials May 16 2015
OncoCyte Corporation Completes Equity Financing Round May 14 2015
OncoCyte Corporation Completes Equity Financing Round May 14 2015
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 14 2015
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s... May 13 2015
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s... May 13 2015
BIOTIME INC Files SEC form 8-K, Other Events May 13 2015
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments May 11 2015
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments May 11 2015
BIOTIME INC Files SEC form 8-K, Results of Operations and Financial Condition May 11 2015
BIOTIME INC Files SEC form 10-Q, Quarterly Report May 08 2015
Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision May 04 2015
Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision May 04 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK